Researchers discover method to 'turn off' mutated melanoma

(Boston University School of Medicine) Melanoma is the deadliest form of skin cancer and notorious for its resistance to conventional chemotherapy. Approximately 25 percent of melanoma is driven by oncogenic mutations in the NRAS gene, making it a very attractive therapeutic target. However, despite decades of research, no effective therapies targeting NRAS have been forthcoming.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news